$KPTI - On our trading list. Good biotech spec play. Performed very well last 6 months or so!Karyopharm price target raised to $27 from $23 at JPMorganJPMorgan analyst Eric Joseph raised his price target for Karyopharm Therapeutics to $27 from $23 ahead of the Phase 3 BOSTON readout this quarter. The analyst sees a high probability of success and a favorable reward/risk profile for the shares. He keeps an Overweight rating on the name. $KPTI, Karyopharm Therapeutics Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page